Ke Ding

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 72

Top Venues

Journal of medicinal chemistry

ACS chemical biology

Science advances

Nature communications

Jinan University

China Pharmaceutical University (MSC)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Jinan University Jun 01 2016

China

professor

Guangzhou Institutes of Biomedicine and Health Mar 01 2006 - Jul 01 2016

China

Professor

University of Michigan Nov 01 2001 - Mar 01 2006

United States

postdoctor/research Investigator

Education History

China Pharmaceutical University Sep 01 1995 - Jul 01 1998

China

MSC

Publications

Yue Liu, Zhongtang Yu, Peishan Li, Tao Yang, Ke Ding, Zhi-Min Zhang, Yi Tan, Zhengqiu Li
Proteome-wide Ligand and Target Discovery by Using Strain-Enabled Cyclopropane Electrophiles. Journal of the American Chemical Society 146 (30) (2024)
Yue Liu, Zhongtang Yu, Peishan Li, Tao Yang, Ke Ding, Zhi-Min Zhang, Yi Tan, Zhengqiu Li
Proteome-wide Ligand and Target Discovery by Using Strain-Enabled Cyclopropane Electrophiles. Journal of the American Chemical Society (2024)
Lianchao Liu, Lijie Zhao, Lujun Yang, Minxue Chai, Zhengyong Liu, Nan Ma, Yongxing Wang, Qinxue Wu, Jing Guo, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Jian Wang, Ming Ding, Zhen Wang, Ke Ding
Discovery of LLC355 as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1. Journal of medicinal chemistry 67 (10) (2024)
Lianchao Liu, Abhijit Parolia, Yihan Liu, Caiyun Hou, Tongchen He, Yuanyuan Qiao, Sanjana Eyunni, Jie Luo, Chungen Li, Yongxing Wang, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Zhen Wang, Arul M Chinnaiyan, Ke Ding
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. Journal of medicinal chemistry 67 (9) (2024)
Lianchao Liu, Abhijit Parolia, Yihan Liu, Caiyun Hou, Tongchen He, Yuanyuan Qiao, Sanjana Eyunni, Jie Luo, Chungen Li, Yongxing Wang, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Zhen Wang, Arul M Chinnaiyan, Ke Ding
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. Journal of medicinal chemistry 67 (9) (2024)
Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Lianchao Liu, Abhijit Parolia, Yihan Liu, Caiyun Hou, Tongchen He, Yuanyuan Qiao, Sanjana Eyunni, Jie Luo, Chungen Li, Yongxing Wang, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Zhen Wang, Arul M Chinnaiyan, Ke Ding
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. Journal of medicinal chemistry 67 (9) (2024)
Lu Liu, Fenghua Chen, Shan Li, Tong Yang, ShuZhen Chen, Yang Zhou, Zejian Lin, Guandi Zeng, Pengju Feng, Hong-Bing Shu, Qian Zhou, Ke Ding, Liang Chen
Human/mouse CD137 agonist, JNU-0921, effectively shrinks tumors through enhancing the cytotoxicity of CD8 + T cells in cis and in trans. Science advances 10 (34) (2024)
Pengpeng Niu, Yanxin Tao, Guohao Lin, Huiqi Xu, Qingyuan Meng, Kang Yang, Weixue Huang, Meiru Song, Ke Ding, Dawei Ma, Mengyang Fan
Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. Journal of medicinal chemistry (2024)
Pengpeng Niu, Yanxin Tao, Guohao Lin, Huiqi Xu, Qingyuan Meng, Kang Yang, Weixue Huang, Meiru Song, Ke Ding, Dawei Ma, Mengyang Fan
Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. Journal of medicinal chemistry 67 (8) (2024)
Lianchao Liu, Abhijit Parolia, Yihan Liu, Caiyun Hou, Tongchen He, Yuanyuan Qiao, Sanjana Eyunni, Jie Luo, Chungen Li, Yongxing Wang, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Zhen Wang, Arul M Chinnaiyan, Ke Ding
Discovery of LLC0424 as a Potent and Selective in Vivo NSD2 PROTAC Degrader. Journal of medicinal chemistry (2024)
Pengpeng Niu, Yanxin Tao, Guohao Lin, Huiqi Xu, Qingyuan Meng, Kang Yang, Weixue Huang, Meiru Song, Ke Ding, Dawei Ma, Mengyang Fan
Design and Synthesis of Novel Macrocyclic Derivatives as Potent and Selective Cyclin-Dependent Kinase 7 Inhibitors. Journal of medicinal chemistry (2024)
Lianchao Liu, Lijie Zhao, Lujun Yang, Minxue Chai, Zhengyong Liu, Nan Ma, Yongxing Wang, Qinxue Wu, Jing Guo, Fengtao Zhou, Weixue Huang, Xiaomei Ren, Jian Wang, Ming Ding, Zhen Wang, Ke Ding
Discovery of LLC355 as an Autophagy-Tethering Compound for the Degradation of Discoidin Domain Receptor 1. Journal of medicinal chemistry (2024)
Shumin Lv, Fang Xu, Youlong Fan, Ke Ding, Zhengqiu Li
Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer. Journal of medicinal chemistry (2023)
Rui He, Zhiqiang Song, Yu Bai, Sheng He, Jing Huang, Yongxing Wang, Fengtao Zhou, Weixue Huang, Jing Guo, Zhen Wang, Zheng-Chao Tu, Xiaomei Ren, Zhang Zhang, Jian Xu, Ke Ding
Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells. Journal of medicinal chemistry 66 (3) (2023)
Shumin Lv, Fang Xu, Youlong Fan, Ke Ding, Zhengqiu Li
Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer. Journal of medicinal chemistry 66 (4) (2023)
Rui He, Zhiqiang Song, Yu Bai, Sheng He, Jing Huang, Yongxing Wang, Fengtao Zhou, Weixue Huang, Jing Guo, Zhen Wang, Zheng-Chao Tu, Xiaomei Ren, Zhang Zhang, Jian Xu, Ke Ding
Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells. Journal of medicinal chemistry (2023)
Shumin Lv, Fang Xu, Youlong Fan, Ke Ding, Zhengqiu Li
Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer. Journal of medicinal chemistry 66 (4) (2023)
Zuqin Wang, Jie Wang, Yongjin Wang, Shuang Xiang, Hengliang Zhou, Shukai Song, Xiaojuan Song, Zhengchao Tu, Yang Zhou, Ke Ding, Zhi-Min Zhang, Zhang Zhang, Xiaoyun Lu
Structure-Based Optimization of the Third Generation Type II Macrocycle TRK Inhibitors with Improved Activity against Solvent-Front, xDFG, and Gatekeeper Mutations. Journal of medicinal chemistry (2023)
Chungen Li, Yuanyuan Qiao, Xia Jiang, Lianchao Liu, Yang Zheng, Yudi Qiu, Caleb Cheng, Fengtao Zhou, Yang Zhou, Weixue Huang, Xiaomei Ren, Yuzhuo Wang, Zhen Wang, Arul M Chinnaiyan, Ke Ding
Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve. Journal of medicinal chemistry (2023)
Shumin Lv, Fang Xu, Youlong Fan, Ke Ding, Zhengqiu Li
Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer. Journal of medicinal chemistry 66 (4) (2023)
Rui He, Zhiqiang Song, Yu Bai, Sheng He, Jing Huang, Yongxing Wang, Fengtao Zhou, Weixue Huang, Jing Guo, Zhen Wang, Zheng-Chao Tu, Xiaomei Ren, Zhang Zhang, Jian Xu, Ke Ding
Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells. Journal of medicinal chemistry 66 (3) (2023)
Ke Ding, Shaomeng Wang, Gunda I Georg, Philip S Portoghese, Dennis C Liotta
In Memory of Professor Hualiang Jiang. Journal of medicinal chemistry (2023)
Shumin Lv, Fang Xu, Youlong Fan, Ke Ding, Zhengqiu Li
Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer. Journal of medicinal chemistry 66 (4) (2023)
Rui He, Zhiqiang Song, Yu Bai, Sheng He, Jing Huang, Yongxing Wang, Fengtao Zhou, Weixue Huang, Jing Guo, Zhen Wang, Zheng-Chao Tu, Xiaomei Ren, Zhang Zhang, Jian Xu, Ke Ding
Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells. Journal of medicinal chemistry 66 (3) (2023)
Zuqin Wang, Jie Wang, Yongjin Wang, Shuang Xiang, Xiaojuan Song, Zhengchao Tu, Yang Zhou, Zhi-Min Zhang, Zhang Zhang, Ke Ding, Xiaoyun Lu
Discovery of the First Highly Selective and Broadly Effective Macrocycle-Based Type II TRK Inhibitors that Overcome Clinically Acquired Resistance. Journal of medicinal chemistry 65 (8) (2022)
Fang Xu, Xin Zhang, Zhipeng Chen, Sheng He, Jing Guo, Lei Yu, Yongjin Wang, Caiyun Hou, Hawaa Ai-Furas, Zongyao Zheng, Jeff B Smaill, Adam V Patterson, Zhi-Min Zhang, Liang Chen, Xiaomei Ren, Ke Ding
Discovery of Isoform-Selective Akt3 Degraders Overcoming Osimertinib-Induced Resistance in Non-Small Cell Lung Cancer Cells. Journal of medicinal chemistry 65 (20) (2022)
Peng Lyu, Kaili Jiang, Yuee Zhou, Jun Hu, Yu Chang, Zhang Zhang, Minhao Huang, Zhi-Min Zhang, Ke Ding, Piliang Hao, Li-Gen Lin, Zhengqiu Li
Proteome-wide Identification of Off-Targets of a Potent EGFR L858R/T790M Mutant Inhibitor. ACS medicinal chemistry letters 13 (2) (2022)
Yue Liu, Jiacong Liu, Xianfang Zhang, Cuiping Guo, Xiwen Xing, Zhi-Min Zhang, Ke Ding, Zhengqiu Li
Oxidant-Induced Bioconjugation for Protein Labeling in Live Cells. ACS chemical biology 18 (1) (2022)
Shan Li, Hongfei Si, Xiaojuan Song, Chong Lei, Xiaoqiang He, Jie Wang, Yiling Liu, Yang Zhou, Jian-Guo Song, Lijie Peng, Xia Tang, Shingpan Chan, Xiaomei Ren, Zhengchao Tu, Zhengqiu Li, Zhen Wang, Zhang Zhang, Ke Ding
Discovery of Hexahydrofuro[3,2- b ]furans as New Kinase-Selective and Orally Bioavailable JAK3 Inhibitors for the Treatment of Leukemia Harboring a JAK3 Activating Mutant. Journal of medicinal chemistry 65 (15) (2022)
Yue Liu, Jiacong Liu, Xianfang Zhang, Cuiping Guo, Xiwen Xing, Zhi-Min Zhang, Ke Ding, Zhengqiu Li
Oxidant-Induced Bioconjugation for Protein Labeling in Live Cells. ACS chemical biology (2022)
Hao Chen, Mengzhen Lai, Tao Zhang, Yuqing Chen, Linjiang Tong, Sujie Zhu, Yang Zhou, Xiaomei Ren, Jian Ding, Hua Xie, Xiaoyun Lu, Ke Ding
Conformational Constrained 4-(1-Sulfonyl-3-indol)yl-2-phenylaminopyrimidine Derivatives as New Fourth-Generation Epidermal Growth Factor Receptor Inhibitors Targeting T790M/C797S Mutations. Journal of medicinal chemistry 65 (9) (2022)
Yue Liu, Jiacong Liu, Xianfang Zhang, Cuiping Guo, Xiwen Xing, Zhi-Min Zhang, Ke Ding, Zhengqiu Li
Oxidant-Induced Bioconjugation for Protein Labeling in Live Cells. ACS chemical biology 18 (1) (2022)
Shengrong Li, Pengwei Zhang, Fang Xu, Shengcao Hu, Jiacong Liu, Yi Tan, Zhengchao Tu, Hongyan Sun, Zhi-Min Zhang, Qing-Yu He, Pinghua Sun, Ke Ding, Zhengqiu Li
Ynamide Electrophile for the Profiling of Ligandable Carboxyl Residues in Live Cells and the Development of New Covalent Inhibitors. Journal of medicinal chemistry 65 (15) (2022)
Zhen Zhang, Jie Li, Hao Chen, Jing Huang, Xiaojuan Song, Zheng-Chao Tu, Zhang Zhang, Lijie Peng, Yang Zhou, Ke Ding
Design, Synthesis, and Biological Evaluation of 2-Formyl Tetrahydronaphthyridine Urea Derivatives as New Selective Covalently Reversible FGFR4 Inhibitors. Journal of medicinal chemistry 65 (4) (2022)
Shan Li, Tao Zhang, Su-Jie Zhu, Chong Lei, Mengzhen Lai, Lijie Peng, Linjiang Tong, Zilu Pang, Xiaoyun Lu, Jian Ding, Xiaomei Ren, Cai-Hong Yun, Hua Xie, Ke Ding
Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR T790M/C797S Mutants. ACS medicinal chemistry letters 13 (2) (2022)
Zhen Wang, Weixue Huang, Kaijie Zhou, Xiaomei Ren, Ke Ding
Targeting the Non-Catalytic Functions: a New Paradigm for Kinase Drug Discovery? Journal of medicinal chemistry 65 (3) (2022)
Yongjin Wang, Yang Zhou, Chaowei Shi, Jiacong Liu, Guohua Lv, Huisi Huang, Shengrong Li, Liping Duan, Xinyi Zheng, Yue Liu, Haibo Zhou, Yonghua Wang, Zhengqiu Li, Ke Ding, Pinghua Sun, Yun Huang, Xiaoyun Lu, Zhi-Min Zhang
A toxin-deformation dependent inhibition mechanism in the T7SS toxin-antitoxin system of Gram-positive bacteria. Nature communications 13 (1) (2022)
Shingpan Chan, Yunong Zhang, Jie Wang, Qiuchun Yu, Xia Peng, Jian Zou, Licheng Zhou, Li Tan, Yunxin Duan, Yang Zhou, Hoon Hur, Jing Ai, Zhen Wang, Xiaomei Ren, Zhang Zhang, Ke Ding
Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors. Journal of medicinal chemistry 65 (22) (2022)
Yue Liu, Jiacong Liu, Xianfang Zhang, Cuiping Guo, Xiwen Xing, Zhi-Min Zhang, Ke Ding, Zhengqiu Li
Oxidant-Induced Bioconjugation for Protein Labeling in Live Cells. ACS chemical biology 18 (1) (2022)
Jibu Lu, Yongjun Huang, Jing Huang, Rui He, Minhao Huang, Xiaoyun Lu, Yong Xu, Fengtao Zhou, Zhang Zhang, Ke Ding
Discovery of the First Examples of Threonine Tyrosine Kinase PROTAC Degraders. Journal of medicinal chemistry 65 (3) (2022)
Jianzhang Yang, Yu Chang, Jean Ching-Yi Tien, Zhen Wang, Yang Zhou, Pujuan Zhang, Weixue Huang, Josh Vo, Ingrid J Apel, Cynthia Wang, Victoria Zhixuan Zeng, Yunhui Cheng, Shuqin Li, George Xiaoju Wang, Arul M Chinnaiyan, Ke Ding
Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13. Journal of medicinal chemistry 65 (16) (2022)
Dennis C Liotta, James C Barrow, Kelly Chibale, Maria Laura Bolognesi, Stuart J Conway, William Alexander Denny, Ke Ding, Stefan A Laufer, Luhua Lai, Hong Liu, Nouri Neamati, Takayoshi Suzuki, Nicholas A Meanwell, Wendy B Young
Simplifying Submission Requirements for the Journal of Medicinal Chemistry. Journal of medicinal chemistry 64 (12) (2021)
Kaili Jiang, Xia Tang, Jing Guo, Rui He, Shingpan Chan, Xiaojuan Song, Zhengchao Tu, Yuting Wang, Xiaomei Ren, Ke Ding, Zhang Zhang
GZD824 overcomes FGFR1-V561F/M mutant resistance in vitro and in vivo. Cancer medicine 10 (14) (2021)
Xiaoyun Lu, Jeff B Smaill, Adam V Patterson, Ke Ding
Discovery of Cysteine-targeting Covalent Protein Kinase Inhibitors. Journal of medicinal chemistry 65 (1) (2021)
Yao Xia, Rongfeng Zou, Maxime Escouboué, Liang Zhong, Chengjun Zhu, Cécile Pouzet, Xueqiang Wu, Yongjin Wang, Guohua Lv, Haibo Zhou, Pinghua Sun, Ke Ding, Laurent Deslandes, Shuguang Yuan, Zhi-Min Zhang
Secondary-structure switch regulates the substrate binding of a YopJ family acetyltransferase. Nature communications 12 (1) (2021)
Yingqiang Liu, Mengzhen Lai, Shan Li, Yanan Wang, Fang Feng, Tao Zhang, Linjiang Tong, Mengge Zhang, Hao Chen, Yi Chen, Peiran Song, Yan Li, Gang Bai, Yi Ning, Haotian Tang, Yan Fang, Yi Chen, Xiaoyun Lu, Meiyu Geng, Ke Ding, Ker Yu, Hua Xie, Jian Ding
LS-106, a novel EGFR inhibitor targeting C797S, exhibits anti-tumor activities both in vitro and in vivo. Cancer science (2021)
Youlong Fan, Hongfei Si, Zhang Zhang, Liang Zhong, Hongyan Sun, Chengjun Zhu, Zhibin Yin, Huilin Li, Guanghui Tang, Shao Q Yao, Pinghua Sun, Zhi-Min Zhang, Ke Ding, Zhengqiu Li
Novel Electrophilic Warhead Targeting a Triple-Negative Breast Cancer Driver in Live Cells Revealed by "Inverse Drug Discovery". Journal of medicinal chemistry 64 (21) (2021)
Zhenzhen Fan, Yahui Tian, Zhipeng Chen, Lu Liu, Qian Zhou, Jingjing He, James Coleman, Changjiang Dong, Nan Li, Junqi Huang, Chenqi Xu, Zhimin Zhang, Song Gao, Penghui Zhou, Ke Ding, Liang Chen
Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. EMBO molecular medicine 12 (6) (2020)
Xiaoyun Lu, Jeff B Smaill, Ke Ding
New Promise and Opportunities for Allosteric Kinase Inhibitors. Angewandte Chemie (International ed. in English) 59 (33) (2020)
Jing Guo, Zhen Zhang, Ke Ding
A patent review of discoidin domain receptor 1 (DDR1) modulators (2014-present). Expert opinion on therapeutic patents 30 (5) (2020)
Hao Chen, Jeff B Smaill, Tongzheng Liu, Ke Ding, Xiaoyun Lu
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics. Journal of medicinal chemistry 63 (23) (2020)
Nan Ma, Jun Hu, Zhi-Min Zhang, Wenyan Liu, Minhao Huang, Youlong Fan, Xingfeng Yin, Jigang Wang, Ke Ding, Wen-Cai Ye, Zhengqiu Li
2H-Azirine-Based Reagents for Chemoselective Bioconjugation at Carboxyl Residues Inside Live Cells. Journal of the American Chemical Society 142 (13) (2020)
Liang Jiang, Xiaolu Wang, Yuting Wang, Fang Xu, Zhang Zhang, Ke Ding, Xiaoyun Lu
The synthesis and biological evaluation of sanguinarine derivatives as anti-non-small cell lung cancer agents. RSC medicinal chemistry 11 (2) (2020)
Xiaoyun Lu, Jeff B Smaill, Ke Ding
Medicinal Chemistry Strategies for the Development of Kinase Inhibitors Targeting Point Mutations. Journal of medicinal chemistry 63 (19) (2020)
Yue-Hong Zhang, Yi-Fang Li, Yongjin Wang, Li Tan, Zhi-Qin Cao, Chao Xie, Guo Xie, Hai-Biao Gong, Wan-Yang Sun, Shu-Hua Ouyang, Wen-Jun Duan, Xiaoyun Lu, Ke Ding, Hiroshi Kurihara, Dan Hu, Zhi-Min Zhang, Leonard Kaysser, Rong-Rong He
Identification and characterization of N9-methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea. Nature communications 11 (1) (2020)
Huihui Ti, Yang Zhou, Xue Liang, Runfeng Li, Ke Ding, Xin Zhao
Targeted Treatments for Chronic Obstructive Pulmonary Disease (COPD) Using Low-Molecular-Weight Drugs (LMWDs). Journal of medicinal chemistry 62 (13) (2019)
Nan Ma, Zhi-Min Zhang, Jun-Seok Lee, Ke Cheng, Ligen Lin, Dong-Mei Zhang, Piliang Hao, Ke Ding, Wen-Cai Ye, Zhengqiu Li
Affinity-Based Protein Profiling Reveals Cellular Targets of Photoreactive Anticancer Inhibitors. ACS chemical biology 14 (12) (2019)
Jiayi Shen, Tao Zhang, Su-Jie Zhu, Min Sun, Linjiang Tong, Mengzhen Lai, Rong Zhang, Wei Xu, Ruibo Wu, Jian Ding, Cai-Hong Yun, Hua Xie, Xiaoyun Lu, Ke Ding
Structure-Based Design of 5-Methylpyrimidopyridone Derivatives as New Wild-Type Sparing Inhibitors of the Epidermal Growth Factor Receptor Triple Mutant (EGFRL858R/T790M/C797S). Journal of medicinal chemistry 62 (15) (2019)
Dongsheng Zhu, Huocong Huang, Daniel M Pinkas, Jinfeng Luo, Debolina Ganguly, Alice E Fox, Emily Arner, Qiuping Xiang, Zheng-Chao Tu, Alex N Bullock, Rolf A Brekken, Ke Ding, Xiaoyun Lu
2-Amino-2,3-dihydro-1H-indene-5-carboxamide-Based Discoidin Domain Receptor 1 (DDR1) Inhibitors: Design, Synthesis, and in Vivo Antipancreatic Cancer Efficacy. Journal of medicinal chemistry 62 (16) (2019)
Jianzhang Yang, Marthandam Asokan Shibu, Lulu Kong, Jinfeng Luo, Farheen BadrealamKhan, Yanhui Huang, Zheng-Chao Tu, Cai-Hong Yun, Chih-Yang Huang, Ke Ding, Xiaoyun Lu
Design, Synthesis, and Structure-Activity Relationships of 1,2,3-Triazole Benzenesulfonamides as New Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. Journal of medicinal chemistry 63 (5) (2019)
Yu Chang, Shilin Xu, Ke Ding
Tyrosine Kinase 2 (TYK2) Allosteric Inhibitors To Treat Autoimmune Diseases. Journal of medicinal chemistry 62 (20) (2019)
Xiaoyun Lu, Zoe Williams, Kiel Hards, Jian Tang, Chen-Yi Cheung, Htin Lin Aung, Bangxing Wang, Zhiyong Liu, Xianglong Hu, Anne Lenaerts, Lisa Woolhiser, Courtney Hastings, Xiantao Zhang, Zhe Wang, Kyu Rhee, Ke Ding, Tianyu Zhang, Gregory M Cook
Pyrazolo[1,5- a]pyridine Inhibitor of the Respiratory Cytochrome bcc Complex for the Treatment of Drug-Resistant Tuberculosis. ACS infectious diseases 5 (2) (2018)
Xiaoyun Lu, Hao Chen, Adam V Patterson, Jeff B Smaill, Ke Ding
Fibroblast Growth Factor Receptor 4 (FGFR4) Selective Inhibitors as Hepatocellular Carcinoma Therapy: Advances and Prospects. Journal of medicinal chemistry 62 (6) (2018)
Zhang Zhang, Jian Zou, Lei Yu, Jinfeng Luo, Yan Li, Zhengchao Tu, Xiaomei Ren, Hongcheng Wei, Liyan Song, Xiaoyun Lu, Ke Ding
YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M -mutant resistance in vitro and in vivo. Cancer medicine 7 (4) (2018)
Xiuyan Yang, Jie Zhong, Qiufen Zhang, Jinxing Qian, Kun Song, Cong Ruan, Jianrong Xu, Ke Ding, Jian Zhang
Rational Design and Structure Validation of a Novel Peptide Inhibitor of the Adenomatous-Polyposis-Coli (APC)-Rho-Guanine-Nucleotide-Exchange-Factor-4 (Asef) Interaction. Journal of medicinal chemistry 61 (17) (2018)
Qiuju Xun, Zhang Zhang, Jinfeng Luo, Linjiang Tong, Minhao Huang, Zhen Wang, Jian Zou, Yingqiang Liu, Yong Xu, Hua Xie, Zheng-Chao Tu, Xiaoyun Lu, Ke Ding
Design, Synthesis, and Structure-Activity Relationship Study of 2-Oxo-3,4-dihydropyrimido[4,5- d]pyrimidines as New Colony Stimulating Factor 1 Receptor (CSF1R) Kinase Inhibitors. Journal of medicinal chemistry 61 (6) (2018)
Maofeng Zhang, Yan Zhang, Ming Song, Xiaoqian Xue, Junjian Wang, Chao Wang, Cheng Zhang, Chenchang Li, Qiuping Xiang, Lingjiao Zou, Xishan Wu, Chun Wu, Baijun Dong, Wei Xue, Yulai Zhou, Hongwu Chen, Donghai Wu, Ke Ding, Yong Xu
Structure-Based Discovery and Optimization of Benzo[ d]isoxazole Derivatives as Potent and Selective BET Inhibitors for Potential Treatment of Castration-Resistant Prostate Cancer (CRPC). Journal of medicinal chemistry 61 (7) (2018)
Zhen Wang, Yali Zhang, Daniel M Pinkas, Alice E Fox, Jinfeng Luo, Huocong Huang, Shengyang Cui, Qiuping Xiang, Tingting Xu, Qiuju Xun, Dongsheng Zhu, Zhengchao Tu, Xiaomei Ren, Rolf A Brekken, Alex N Bullock, Guang Liang, Ke Ding, Xiaoyun Lu
Design, Synthesis, and Biological Evaluation of 3-(Imidazo[1,2- a]pyrazin-3-ylethynyl)-4-isopropyl- N-(3-((4-methylpiperazin-1-yl)methyl)-5-(trifluoromethyl)phenyl)benzamide as a Dual Inhibitor of Discoidin Domain Receptors 1 and 2. Journal of medicinal chemistry 61 (17) (2018)
Jian Zou, Zhang Zhang, Fang Xu, Shengyang Cui, Chunli Qi, Jinfeng Luo, Zhen Wang, Xiaoyun Lu, Zhengchao Tu, Xiaomei Ren, Liyan Song, Ke Ding
GZD2202, a novel TrkB inhibitor, suppresses BDNF-mediated proliferation and metastasis in neuroblastoma models. Journal of drug targeting 27 (4) (2018)
Yu Chang, Xiaoyun Lu, Marthandam Asokan Shibu, Yi-Bo Dai, Jinfeng Luo, Yan Zhang, Yingjun Li, Peng Zhao, Zhang Zhang, Yong Xu, Zheng-Chao Tu, Qing-Wen Zhang, Cai-Hong Yun, Chih-Yang Huang, Ke Ding
Structure Based Design of N-(3-((1H-Pyrazolo[3,4-b]pyridin-5-yl)ethynyl)benzenesulfonamides as Selective Leucine-Zipper and Sterile-α Motif Kinase (ZAK) Inhibitors. Journal of medicinal chemistry 60 (13) (2017)

Ke Ding.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Ke Ding